Portfolio company
Immitra Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
7 investors
Sectors
About
This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Spot Biosystems
This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
LogicBio
This company develops gene editing and delivery platforms to provide one-time treatments for patients with serious, early-onset rare genetic diseases.
Chameleon Biosciences
This company develops immune-evading gene therapy delivery platforms for pharmaceutical firms and patients with genetic disorders.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
SonoThera™
This company develops an ultrasound-guided non-viral platform to deliver genetic medicines for patients with chronic and rare diseases.
Replay Therapeutics
This biotech company develops genome writing and delivery platforms to provide genetic medicines for patients with rare skin, eye and haematological diseases.
Airna
This company develops RNA editing therapeutics to treat patients with rare genetic and common cardiometabolic diseases.